AZILECT(TM) (rasagiline mesylate tablets), the first once-daily oral treatment for Parkinson’s disease (PD) has just been approved by Health Canada. The drug is approved for use as initial monotherapy in early PD and as adjunct therapy to levodopa in moderate-to-advanced disease. It is expected to become available over the next few weeks in two dosage strengths.
